about
Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance--NO and MMP-9 interactionsHeart failure in sub-Saharan Africa: review of the aetiology of heart failure and the role of point-of-care biomarker diagnosticsGetting to the heart of cardiac remodeling; how collagen subtypes may contribute to phenotype.Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes.Heart failure management programs: can we afford to ignore the inpatient phase of care?MicroRNA signatures differentiate preserved from reduced ejection fraction heart failureDiagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover.B-type natriuretic peptide measurement in primary care; magnitude of associations with cardiovascular risk factors and their therapies. Observations from the STOP-HF (St. Vincent's Screening TO Prevent Heart Failure) study.Are beta2-agonists responsible for increased mortality in heart failure?The St Vincent's potentially inappropriate medicines study: development of a disease-specific consensus list and its evaluation in ambulatory heart failure care.Life expectancy for community-based patients with heart failure from time of diagnosis.Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care.Role of Monitoring Devices in Preventing Heart Failure Admissions.A Central Role for Monocyte-Platelet Interactions in Heart Failure.Heart Failure Virtual Consultation: bridging the gap of heart failure care in the community - A mixed-methods evaluation.Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis.Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide.Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up.Diagnosis of new onset heart failure in the community: the importance of a shared-care approach and judicious use of BNP.Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-convertinNeed and evolution of need for device therapy in a community heart failure population.Profiling B-type natriuretic peptide in a stable heart failure population: a valuable adjunct to care.Quality of life predicts outcome in a heart failure disease management program.Specialist nurse supervised in-hospital titration to target dose ACE inhibitor--is it safe and feasible in a community heart failure population?Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure.Novel Iron-Whey Protein Microspheres Protect Gut Epithelial Cells from Iron-Related Oxidative Stress and Damage and Improve Iron Absorption in Fasting Adults.Can individualized weight monitoring using the HeartPhone algorithm improve sensitivity for clinical deterioration of heart failure?Clinical deterioration in established heart failure: what is the value of BNP and weight gain in aiding diagnosis?Intrauterine insemination-No more Mr. N.I.C.E. guy?B-Type Natriuretic Peptide and Ventricular Dysfunction in the Prediction of Cardiovascular Events and Death in Hypertension.Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study.Elevated BNP with normal systolic function in asymptomatic individuals at-risk for heart failure: a marker of diastolic dysfunction and clinical risk.Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.Screening to prevent heart failure (STOP-HF): expanding the focus beyond asymptomatic left ventricular systolic dysfunction.Clinical and psychological impact of prophylactic implantable cardioverter-defibrillators in a community heart failure population.Diabetes and complications of the heart in Sub-Saharan Africa: An urgent need for improved awareness, diagnostics and management.A comparison of HFrEF vs HFpEF's clinical workload and cost in the first year following hospitalization and enrollment in a disease management program.Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure.
P50
Q26863515-BC9788E7-812D-4BEC-9303-AC17B328824AQ27015261-5C840B0B-1BBB-483E-9D4A-9657655FC9DDQ34050866-8A162CD3-A5B6-47D0-8C82-F6F4559DC149Q34477882-D995A296-B6FC-4C57-83B1-DAEB09670C31Q35299862-8D183936-CF41-4BB2-9BBA-9EBA33B54765Q35565357-1BBB7F4C-DD02-4BC2-885A-99D451BB4559Q37090982-97B3C1A0-0318-4A61-94F7-F74A84533AFBQ37833104-BB30AFC3-D6DA-4ACD-8263-3123A139A9B1Q37906050-9031649D-B225-4819-9E97-E5809FD2C9E5Q38237578-95413454-4AD2-42F5-98A0-2B3797685FCCQ38281239-4D38548C-15F8-442A-85AA-FD5411D01AF8Q38448978-64720E14-BB4E-4A29-9325-155ACEE16DD7Q38486389-A17307B0-4570-4B6B-BD7B-0583EEE64BC8Q38517990-E5CFEFB2-F873-42AE-86C6-46BEE7A05686Q38620927-A279ADB0-32DD-433E-8E58-70357356BB87Q38643988-F2FF7BE9-0EC7-467E-B70E-53F4BCE9C9EBQ38858284-3747425E-0505-4F5D-8F29-995AA5FBD2ABQ39159036-31826CBC-C310-4E50-B48A-3F4E29C1433CQ40809782-E7ADAA29-4874-4673-AB2B-0D666642E6AEQ42662404-D3637E81-649B-47F6-9B57-621D988A1C0DQ43256623-CBB4FB48-561E-4483-8A60-DE5C309F2197Q43540803-B9BA29DE-7805-4418-A749-5C7A6341BAF6Q44132952-B2E65037-31C1-4382-9FBA-1540EAEFC65DQ44273778-BB390B09-023B-430D-A9CB-A7FD31F29210Q44281471-A0BF2025-5D98-4E06-AAE5-07980F20E13EQ44658582-0B1058F1-0F8C-4410-BE16-B16CFFCCA7ABQ46727216-C61F748C-9EE1-4AA7-8DF7-804208BBB602Q47232455-4D37AA11-E52D-4E78-B13F-B7AFD7515C73Q47269095-914E9721-D86C-49CF-958F-9FFB104A5403Q47365183-4DF0E5C5-E206-4392-85F1-3D13E44EA3E3Q47577596-C9CB45A7-4356-4195-B75C-5D401C68BF5EQ47785292-571D4BA0-BEEF-4C0A-86AF-36EB7589266EQ48096616-DDE0AF9F-F961-4BA0-ACF6-A52AB8413A81Q48267596-303150AB-12B5-421C-A594-D9EEB6F12E01Q48270321-DF198E0B-1DEC-4217-B1DF-43162FD06B96Q48615907-1A7252D8-A017-4CE0-BEC2-7EA1F84484CCQ48729170-B10874D0-A022-47A1-BE34-A72783FAF70CQ49487884-AA1659AD-DD73-4D90-9BFF-AF04D4577772Q51329353-7B204471-3EB7-469E-8313-604658EEE7A1Q52141958-E20C3BB8-F234-4265-B233-DBF8A20BCF0F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark T Ledwidge
@ast
Mark T Ledwidge
@en
Mark T Ledwidge
@es
Mark T Ledwidge
@nl
type
label
Mark T Ledwidge
@ast
Mark T Ledwidge
@en
Mark T Ledwidge
@es
Mark T Ledwidge
@nl
prefLabel
Mark T Ledwidge
@ast
Mark T Ledwidge
@en
Mark T Ledwidge
@es
Mark T Ledwidge
@nl
P106
P31
P496
0000-0001-7391-2949